Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Mattel Inc (MAT) Price & Performance

Iovance Biotherapeutics Inc. Common StockTrade
Mattel IncTrade

Price performance (Past 24H)

Key statistics

Iovance Biotherapeutics Inc. Common Stock vs Mattel Inc — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.69 (market cap $6.04B), while Mattel Inc trades at $16.67 (market cap $4.74B). The key difference: Iovance Biotherapeutics Inc. Common Stock is the larger of the two by market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, Mattel Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Mattel Inc for 97 Days on average.

IOVAMAT
Market Cap
$6.04B$4.74B
Volume
14,805,99311,809,722
Sector
HealthConsumer Cyclical
52-Week High
$14.82$22.16
52-Week Low
$1.81$12.66
Typical Hold Time
0 Days97 Days
Enterprise Value
$5.97B$6.96B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Iovance Biotherapeutics Inc. Common Stock

No Aura AI signal available yet.

Mattel Inc

Mattel (MAT) trades at $17.12, up 4.58% amid takeover speculation from Authentic Brands Group. The stock shows bullish technical signals with strong moving average support, though RSI levels indicate overbought conditions. Fundamentally, the company maintains solid profitability with 7.78% net margins and 20.5% ROE, though recent earnings have been mixed with two misses in the last three quarters. Leadership transition is underway with Roger Lynch replacing Ynon Kreiz as CEO.

The takeover interest creates near-term upside potential, but execution risks remain under new leadership. Analyst consensus is bullish with 53% buy ratings and $15 price target, though current price exceeds target. Key risks include Barbie sales deterioration, integration challenges for new CEO, and declining operating cash flow from $870M in 2023 to $593M in 2025.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

IOVA
51% Buy49% Sell
Avg holding period · 0 Days
MAT
2% Buy98% Sell
Avg holding period · 97 Days

Top news

Latest headlines on both assets

About Iovance Biotherapeutics Inc. Common Stock

Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.

Read more on IOVA →

About Mattel Inc

Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.

Read more on MAT →